Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme


Increased tryptophan (Trp) catabolism in the tumor microenvironment (TME) can mediate immune suppression by upregulation of interferon (IFN)-γ-inducible indoleamine 2,3-dioxygenase (IDO1) and/or ectopic expression of the predominantly liver-restricted enzyme tryptophan 2,3-dioxygenase (TDO)1,2,3,4,5. Whether these effects are due to Trp depletion in the TME or mediated by the accumulation of the IDO1 and/or TDO (hereafter referred to as IDO1/TDO) product kynurenine (Kyn) remains controversial5,6,7,8,9,10,11,12,13. Here we show that administration of a pharmacologically optimized enzyme (PEGylated kynureninase; hereafter referred to as PEG-KYNase) that degrades Kyn into immunologically inert, nontoxic and readily cleared metabolites inhibits tumor growth. Enzyme treatment was associated with a marked increase in the tumor infiltration and proliferation of polyfunctional CD8+ lymphocytes. We show that PEG-KYNase administration had substantial therapeutic effects when combined with approved checkpoint inhibitors or with a cancer vaccine for the treatment of large B16-F10 melanoma, 4T1 breast carcinoma or CT26 colon carcinoma tumors. PEG-KYNase mediated prolonged depletion of Kyn in the TME and reversed the modulatory effects of IDO1/TDO upregulation in the TME.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Kynureninase administration reduces tumor growth by depleting kynurenine from the tumor microenvironment.
Figure 2: Kynureninase treatment increases the frequency of effector CD8+ TILs.
Figure 3: Combination of PEG-kynureninase with other immunotherapies for the treatment of large, established tumors in multiple tumor models.


  1. 1

    Cheong, J.E. & Sun, L. Targeting the IDO1–TDO2–KYN–AHR pathway for cancer immunotherapy—challenges and opportunities. Trends Pharmacol. Sci. 39, 307–325 (2018).

    CAS  Article  Google Scholar 

  2. 2

    Prendergast, G.C., Malachowski, W.P., DuHadaway, J.B. & Muller, A.J. Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res. 77, 6795–6811 (2017).

    CAS  Article  Google Scholar 

  3. 3

    Munn, D.H. & Mellor, A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117, 1147–1154 (2007).

    CAS  Article  Google Scholar 

  4. 4

    Badawy, A.A.-B., Namboodiri, A.M.A. & Moffett, J.R. The end of the road for the tryptophan depletion concept in pregnancy and infection. Clin. Sci. (Lond.) 130, 1327–1333 (2016).

    CAS  Article  Google Scholar 

  5. 5

    Sonner, J.K. et al. The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. OncoImmunology 5, e1240858 (2016).

    Article  Google Scholar 

  6. 6

    Van de Velde, L.-A. et al. Stress kinase GCN2 controls the proliferative fitness and trafficking of cytotoxic T cells independent of environmental amino acid sensing. Cell Rep. 17, 2247–2258 (2016).

    CAS  Article  Google Scholar 

  7. 7

    Platten, M., Wick, W. & Van den Eynde, B.J. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 72, 5435–5440 (2012).

    CAS  Article  Google Scholar 

  8. 8

    Puccetti, P. et al. Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. PLoS One 10, e0122046 (2015).

    Article  Google Scholar 

  9. 9

    Fatokun, A.A., Hunt, N.H. & Ball, H.J. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease. Amino Acids 45, 1319–1329 (2013).

    CAS  Article  Google Scholar 

  10. 10

    Spranger, S. et al. Upregulation of PD-L1, IDO and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5, 200ra116 (2013).

    Article  Google Scholar 

  11. 11

    Mondanelli, G. et al. A Relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity 46, 233–244 (2017).

    CAS  Article  Google Scholar 

  12. 12

    Holmgaard, R.B., Zamarin, D., Munn, D.H., Wolchok, J.D. & Allison, J.P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA4. J. Exp. Med. 210, 1389–1402 (2013).

    CAS  Article  Google Scholar 

  13. 13

    Ninomiya, S. et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125, 3905–3916 (2015).

    CAS  Article  Google Scholar 

  14. 14

    Spranger, S. et al. Mechanism of tumor rejection with doublets of CTLA4, PD-1–PD-L1 or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J. Immunother. Cancer 2, 3 (2014).

    Article  Google Scholar 

  15. 15

    Thaker, A.I. et al. IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology 145, 416–425 (2013).

    CAS  Article  Google Scholar 

  16. 16

    Mezrich, J.D. et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190–3198 (2010).

    CAS  Article  Google Scholar 

  17. 17

    Opitz, C.A. et al. An endogenous tumor-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197–203 (2011).

    CAS  Article  Google Scholar 

  18. 18

    Seok, S.-H. et al. Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR). J. Biol. Chem. 293, 1994–2005 (2018).

    CAS  Article  Google Scholar 

  19. 19

    Theofylaktopoulou, D. et al. A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clin. Exp. Immunol. 173, 121–130 (2013).

    CAS  Article  Google Scholar 

  20. 20

    Vécsei, L., Szalárdy, L., Fülöp, F. & Toldi, J. Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov. 12, 64–82 (2013).

    Article  Google Scholar 

  21. 21

    Cervenka, I., Agudelo, L.Z. & Ruas, J.L. Kynurenines: tryptophan's metabolites in exercise, inflammation and mental health. Science 357, eaaf9794 (2017).

    Article  Google Scholar 

  22. 22

    Phillips, R.S. Structure and mechanism of kynureninase. Arch. Biochem. Biophys. 544, 69–74 (2014).

    CAS  Article  Google Scholar 

  23. 23

    Stone, E. et al. Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy. J. Control. Release 158, 171–179 (2012).

    CAS  Article  Google Scholar 

  24. 24

    Frumento, G. et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196, 459–468 (2002).

    CAS  Article  Google Scholar 

  25. 25

    Hou, D.-Y. et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67, 792–801 (2007).

    CAS  Article  Google Scholar 

  26. 26

    Banerjee, T. et al. A key in vivo antitumor mechanism of action of natural-product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 27, 2851–2857 (2008).

    CAS  Article  Google Scholar 

  27. 27

    Levina, V., Su, Y. & Gorelik, E. Immunological and non-immunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation. Clin. Dev. Immunol. 2012, 173029 (2012).

    Article  Google Scholar 

  28. 28

    Pagès, F. et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 27, 5944–5951 (2009).

    Article  Google Scholar 

  29. 29

    Yuan, J. et al. CTLA4 blockade enhances polyfunctional NY-ESO-1-specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. USA 105, 20410–20415 (2008).

    CAS  Article  Google Scholar 

  30. 30

    Wainwright, D.A. et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA4 and PD-L1 in mice with brain tumors. Clin. Cancer Res. 20, 5290–5301 (2014).

    CAS  Article  Google Scholar 

  31. 31

    Holmgaard, R.B., Zamarin, D., Lesokhin, A., Merghoub, T. & Wolchok, J.D. Targeting myeloid-derived suppressor cells with colony stimulating factor–1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase–expressing tumors. EBioMedicine 6, 50–58 (2016).

    Article  Google Scholar 

  32. 32

    Grosso, J.F. & Jure-Kunkel, M.N. CTLA4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13, 5 (2013).

    PubMed  PubMed Central  Google Scholar 

  33. 33

    Schreiber, T.H., Raez, L., Rosenblatt, J.D. & Podack, E.R. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin. Immunol. 22, 105–112 (2010).

    CAS  Article  Google Scholar 

  34. 34

    Chung, K.-T. & Gadupudi, G.S. Possible roles of excess tryptophan metabolites in cancer. Environ. Mol. Mutagen. 52, 81–104 (2011).

    CAS  Article  Google Scholar 

  35. 35

    Moyer, B.J. et al. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor. Toxicol. Appl. Pharmacol. 323, 74–80 (2017).

    CAS  Article  Google Scholar 

  36. 36

    Terness, P. et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase–expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196, 447–457 (2002).

    CAS  Article  Google Scholar 

  37. 37

    Sierra, J.R., Cepero, V. & Giordano, S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer 9, 75 (2010).

    Article  Google Scholar 

  38. 38

    Matino, D. et al. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J. Clin. Invest. 125, 3766–3781 (2015).

    Article  Google Scholar 

  39. 39

    Koushik, S.V., Sundararaju, B., McGraw, R.A. & Phillips, R.S. Cloning, sequence and expression of kynureninase from Pseudomonas fluorescens. Arch. Biochem. Biophys. 344, 301–308 (1997).

    CAS  Article  Google Scholar 

  40. 40

    Miroux, B. & Walker, J.E. Overproduction of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J. Mol. Biol. 260, 289–298 (1996).

    CAS  Article  Google Scholar 

Download references


We are grateful to N. Ashoura for assistance with various aspects of this work, data interpretation and comments on the manuscript. This work was supported by funding from NIH 1 RO1 CA189623 (E. Stone and G.G.), the Cancer Prevention and Research Institute of Texas grant DP150061 (E. Stone, L.I.R.E. and G.G.) and Kyn Therapeutics (G.G. and E. Stone). Support from the American Cancer Society was provided to T.A.T. (Postdoctoral Fellowship 126584-PF-14-216-01-TBF), N.M. (Postdoctoral Fellowship 123506-PF-13-354-01-CDD) and J.B. (Postdoctoral Fellowship 128252-PF-15-143-01-CDD). M.D. acknowledges support by a postdoctoral fellowship from the Cancer Prevention and Research Institute of Texas (RP140108).

Author information




T.A.T., K.C.G., N.M. and M.D. designed and performed key experiments; J.B., C.L., A.Q., B.T., Y.T., W.-C.L., C.S.K., K.F. and M.S.Y. expressed, cloned, characterized and prepared enzymes for in vitro and in vivo studies; B.T. and Y.K. developed and performed pharmacokinetic assays; J.D.D., M.M., X.M.Z., G.F., K.M., S.C. and T.H.S. designed and performed certain in vivo and in vitro experiments; E. Sentandreu and S.T. performed metabolomics analyses; T.A.T., K.C.G., M.D., J.D.D., L.I.R.E., G.G. and E. Stone interpreted the data; and G.G., T.A.T., K.C.G. and E. Stone wrote the manuscript.

Corresponding authors

Correspondence to Everett Stone or George Georgiou.

Ethics declarations

Competing interests

G.G. and E. Stone are inventors on intellectual property related to this work, and G.G., E. Stone, X.M.Z., K.M., S.C. and M.M. have equity interest in Kyn Therapeutics, a company pursuing the commercial development of this technology.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–18 and Supplementary Tables 1–2 (PDF 3320 kb)

Life Sciences Reporting Summary (PDF 255 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Triplett, T., Garrison, K., Marshall, N. et al. Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nat Biotechnol 36, 758–764 (2018).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing